Piper Jaffray is out with its report today on Alnylam Pharmaceuticals ALNY, upgrading ALNY to Overweight from Neutral.
In its report, Piper Jaffray writes, "We look for upside as Alnylam reports Phase I proof-of-concept data on orphan drug ALN-TTR01 and high cholesterol drug ALN-PCS both in 4Q:11. In addition, Alnylam offers an attractive way to invest in Regulus Therapeutics, the preeminent microRNA play. We are upgrading Alnylam to Overweight from Neutral and increasing our price target to $12 from $10."
Shares of ALNY closed Monday at $7.34, up 6.38% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in